Abstract
Objective To evaluate the clinical value of compound bone peptide injection in patients with thoracolumbar osteoporotic fracture. Methods 96 patients admitted from January 2018 to January 2020 with thoracolumbar osteoporotic fracture were selected. The patients were randomly divided into group A (receiving calcine D with compound bone peptide injection) and group B (receiving calcine D treatment) with 48 patients in each group. TCM symptom scores, bone metabolism, degree of osteoporosis, bone density level, visual analogue scale (VAS) and lumbar spine disease treatment score (JOA) were compared between the two groups after treatment. Results After treatment, the TCM symptom score and JOA score in group A were higher than those in group B (P Conclusion The treatment of thoracolumbar osteoporotic fracture with compound bone peptide injection effectively improved the bone metabolism and bone mineral density, relieved pain and promoted the recovery of lumbar function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
